AI-Assisted Ki-67 Scoring to Improve Diagnostic Reproducibility in Sarcomas

Singapore, January 25, 2025 — Qritive’s peer-reviewed publication in Heliyon highlights one of the recent advancements in AI-assisted pathology, focusing on improving the consistency of Ki-67 proliferative index scoring in soft tissue sarcomas.

Improving the Accuracy of Reporting Ki-67 IHC by Using an AI Tool

Heliyon, Volume 10, Issue 22, Article e40193 | 30 November 2024

This study introduces a traditional computer vision–based AI module designed to support pathologists in evaluating Ki-67 proliferative index (PI) on IHC-stained whole-slide images. Applied to sarcoma cases, the AI system significantly reduced inter-observer variability and improved concordance between pathologists, especially in regions of interest with complex morphology.

Read the Full Article on ScienceDirect

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com